Drug therapy and new technology progress of type 2 diabetes mellitus
10.12092/j.issn.1009-2501.2025.09.008
- VernacularTitle:2型糖尿病的药物治疗及新技术进展
- Author:
Xing LIU
1
;
Ying CHEN
1
Author Information
1. 复旦大学附属中山医院内分泌科,上海 200032
- Publication Type:Journal Article
- Keywords:
type 2 diabetes mellitus;
drug thera-py;
artificial intelligence
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(9):1215-1223
- CountryChina
- Language:Chinese
-
Abstract:
As the incidence of diabetes in China continues to rise,its complications pose a serious threat to the life health of patients.New hypoglyce-mic agents are constantly emerging,with particular attention being paid to glucagon-like peptide-1 re-ceptor agonists(GLP-1RA)and sodium-glucose co-transporter 2 inhibitor(SGLT2i),which can not only effectively control blood glucose levels,but also sig-nificantly improve the cardiac and renal outcomes of diabetic patients.New technologies for diabetes management based on artificial intelligence(AI)are also developing rapidly,playing a crucial role in the diagnosis of diabetic retinopathy(DR)and insu-lin dose-assisted decision-making.Continuous glu-cose monitoring(CGM)and automated insulin de-livery system(AID)have already been used clinical-ly.This article reviews the progress in drug therapy and new technologies for type 2 diabetes mellitus T2DM,aiming to provide guidance for the treat-ment of T2DM patients.
